183 related articles for article (PubMed ID: 33867195)
1. [EBV and immunodeficiency].
Dieudonne Y; Martin M; Korganow AS; Boutboul D; Guffroy A
Rev Med Interne; 2021 Dec; 42(12):832-843. PubMed ID: 33867195
[TBL] [Abstract][Full Text] [Related]
2. Severe Epstein-Barr virus infection in primary immunodeficiency and the normal host.
Worth AJ; Houldcroft CJ; Booth C
Br J Haematol; 2016 Nov; 175(4):559-576. PubMed ID: 27748521
[TBL] [Abstract][Full Text] [Related]
3. Inherited Immunodeficiencies With High Predisposition to Epstein-Barr Virus-Driven Lymphoproliferative Diseases.
Latour S; Winter S
Front Immunol; 2018; 9():1103. PubMed ID: 29942301
[TBL] [Abstract][Full Text] [Related]
4. Primary immunodeficiencies predisposed to Epstein-Barr virus-driven haematological diseases.
Parvaneh N; Filipovich AH; Borkhardt A
Br J Haematol; 2013 Sep; 162(5):573-86. PubMed ID: 23758097
[TBL] [Abstract][Full Text] [Related]
5. When to suspect inborn errors of immunity in Epstein-Barr virus-related lymphoproliferative disorders.
Sacco KA; Notarangelo LD; Delmonte OM
Clin Microbiol Infect; 2023 Apr; 29(4):457-462. PubMed ID: 36209991
[TBL] [Abstract][Full Text] [Related]
6. A Case of severe mosquito bite allergy complicated by fatal hemophagocytic lymphohistiocytosis.
Dupuy E; Afifi L; Jonas SJ; Cheng CE; Hogeling M
Pediatr Dermatol; 2022 May; 39(3):443-446. PubMed ID: 35322460
[TBL] [Abstract][Full Text] [Related]
7. X-linked Lymphoproliferative Disease (XLP1) Presenting as Non-Epstein Barr Virus (EBV) - Related Hemophagocytic Lymphohistiocytosis (HLH).
Loganathan A; Munirathnam D; Sundaram B
Indian Pediatr; 2020 Nov; 57(11):1077-1078. PubMed ID: 33231181
[No Abstract] [Full Text] [Related]
8. Spectrum of Epstein-Barr virus-associated T-cell lymphoproliferative disorder in adolescents and young adults in Taiwan.
Wang RC; Chang ST; Hsieh YC; Huang WT; Hsu JD; Tseng CE; Wang MC; Hwang WS; Wang J; Chuang SS
Int J Clin Exp Pathol; 2014; 7(5):2430-7. PubMed ID: 24966953
[TBL] [Abstract][Full Text] [Related]
9. Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases.
Latour S; Fischer A
Immunol Rev; 2019 Sep; 291(1):174-189. PubMed ID: 31402499
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr Virus (EBV)-induced B-cell Lymphoproliferative Disorder Mimicking the Recurrence of EBV-associated Hemophagocytic Lymphohistiocytosis.
Yatsushiro Y; Nishikawa T; Saito A; Nakazawa Y; Imadome KI; Nakagawa S; Kodama Y; Okamoto Y; Kanegane H; Kawano Y
J Pediatr Hematol Oncol; 2019 Jan; 41(1):e44-e46. PubMed ID: 29324572
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus: dermatologic associations and implications: part II. Associated lymphoproliferative disorders and solid tumors.
Eminger LA; Hall LD; Hesterman KS; Heymann WR
J Am Acad Dermatol; 2015 Jan; 72(1):21-34; quiz 35-6. PubMed ID: 25497918
[TBL] [Abstract][Full Text] [Related]
12. Serious consequences of Epstein-Barr virus infection: Hemophagocytic lymphohistocytosis.
Xu L; Guo X; Guan H
Int J Lab Hematol; 2022 Feb; 44(1):74-81. PubMed ID: 34709704
[TBL] [Abstract][Full Text] [Related]
13. The immunology of Epstein-Barr virus-induced disease.
Taylor GS; Long HM; Brooks JM; Rickinson AB; Hislop AD
Annu Rev Immunol; 2015; 33():787-821. PubMed ID: 25706097
[TBL] [Abstract][Full Text] [Related]
14. Primary immunodeficiencies associated with EBV-Induced lymphoproliferative disorders.
Shabani M; Nichols KE; Rezaei N
Crit Rev Oncol Hematol; 2016 Dec; 108():109-127. PubMed ID: 27931829
[TBL] [Abstract][Full Text] [Related]
15. Dual Threat of Epstein-Barr Virus: an Autopsy Case Report of HIV-Positive Plasmablastic Lymphoma Complicating EBV-Associated Hemophagocytic Lymphohistiocytosis.
Koizumi Y; Imadome KI; Ota Y; Minamiguchi H; Kodama Y; Watanabe D; Mikamo H; Uehira T; Okada S; Shirasaka T
J Clin Immunol; 2018 May; 38(4):478-483. PubMed ID: 29687211
[TBL] [Abstract][Full Text] [Related]
16. Haemophagocytic lymphohistiocytosis and Epstein-Barr virus: a complex relationship with diverse origins, expression and outcomes.
El-Mallawany NK; Curry CV; Allen CE
Br J Haematol; 2022 Jan; 196(1):31-44. PubMed ID: 34169507
[TBL] [Abstract][Full Text] [Related]
17. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis.
Balamuth NJ; Nichols KE; Paessler M; Teachey DT
J Pediatr Hematol Oncol; 2007 Aug; 29(8):569-73. PubMed ID: 17762500
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus-induced hemophagocytic lymphohistiocytosis and X-linked lymphoproliferative disease: a mimicker of sepsis in the pediatric intensive care unit.
Mischler M; Fleming GM; Shanley TP; Madden L; Levine J; Castle V; Filipovich AH; Cornell TT
Pediatrics; 2007 May; 119(5):e1212-8. PubMed ID: 17403820
[TBL] [Abstract][Full Text] [Related]
19. A case of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis with severe cardiac complications.
Kawamura Y; Miura H; Matsumoto Y; Uchida H; Kudo K; Hata T; Ito Y; Kimura H; Yoshikawa T
BMC Pediatr; 2016 Oct; 16(1):172. PubMed ID: 27793118
[TBL] [Abstract][Full Text] [Related]
20. Development of Epstein-Barr virus-associated lymphoproliferative disorder and hemophagocytic lymphohistiocytosis during long-term lenalidomide maintenance therapy in multiple myeloma.
Yoshida M; Morita K; Fukushima H; Jona M; Nishikawa M; Yatomi Y; Kishino Y; Iwasaki A; Ushiku T; Imadome KI; Honda A; Maki H; Kurokawa M
Int J Hematol; 2023 May; 117(5):769-773. PubMed ID: 36510096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
